First Reported Case of Pure Red Cell Aplasia Related to Sotorasib
We herein report a 64-year-old man with KRAS<sup>G12C</sup>-mutated advanced lung adenocarcinoma previously treated with immune checkpoint inhibitors (ICIs). One month after starting second-line sotorasib treatment, the patient experienced a progressive decline in serum hemoglobin levels. Anemia was accompanied by markedly elevated serum erythropoietin levels and decreased reticulocyte levels. Bone marrow aspiration revealed pure red cell aplasia. No secondary causes other than medication use were identified. Suspected causative drugs were sotorasib and ICIs. Discontinuation of sotorasib for one week improved his anemia; therefore, the causative drug was identified as sotorasib.
Authors
- Hiroki Tahara
- Yuya Nakata (ORCID: https://orcid.org/0009-0001-5024-7306)
- Jun Shiihara
- Motoko Nomura (ORCID: https://orcid.org/0000-0002-8915-1846)
- Hiromitsu Ohta (ORCID: https://orcid.org/0000-0001-9893-0254)
- Yoshiaki Nagai (ORCID: https://orcid.org/0000-0001-9466-8324)
- Nozomu Yoshino (ORCID: https://orcid.org/0000-0002-5400-6497)
- Hikari Amari
- Yasuhiro Yamaguchi (ORCID: https://orcid.org/0000-0002-6899-4406)
- Yuki K. Maeda (ORCID: https://orcid.org/0000-0001-6460-029X)
- Tatsuya Saito
- Katsuhiro Itogawa
Institutions
- Jichi Medical University (JP)
- Jichi Medical University Saitama Medical Center (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2024-09-03
- DOI
- https://doi.org/10.2169/internalmedicine.3961-24
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.88